.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Long-term follow-up from the Swedish Spinal Stenosis Study adds important durability to the evidence comparing decompression alone with decompression plus fusion. At five years, disability outcomes were similar between groups, regardless of whether degenerative spondylolisthesis was present. The results reinforce the lack of a routine clinical advantage from adding fusion to decompression for many patients with lumbar spinal stenosis. Fusion increased operative burden without improving the main patient-reported endpoint. This evidence is directly relevant to surgical planning because it challenges the common assumption that a radiographic slip should automatically trigger fusion. For HCPs, decision-making should instead focus on symptoms, instability, deformity, level of disease and the goals of surgery. Older patients may particularly benefit from avoiding unnecessary blood loss, longer hospitalisation and added implant-related risks. The broader message is that less extensive surgery can deliver equivalent long-term outcomes when it addresses the actual source of symptoms. Fusion remains appropriate for selected patients, but this trial supports treating it as an indication-specific procedure rather than an automatic companion to decompression.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Long-term follow-up from the Swedish Spinal Stenosis Study adds important durability to the evidence comparing decompression alone with decompression plus fusion. At five years, disability outcomes were similar between groups, regardless of whether degenerative spondylolisthesis was present. The results reinforce the lack of a routine clinical advantage from adding fusion to decompression for many patients with lumbar spinal stenosis. Fusion increased operative burden without improving the main patient-reported endpoint. This evidence is directly relevant to surgical planning because it challenges the common assumption that a radiographic slip should automatically trigger fusion. For HCPs, decision-making should instead focus on symptoms, instability, deformity, level of disease and the goals of surgery. Older patients may particularly benefit from avoiding unnecessary blood loss, longer hospitalisation and added implant-related risks. The broader message is that less extensive surgery can deliver equivalent long-term outcomes when it addresses the actual source of symptoms. Fusion remains appropriate for selected patients, but this trial supports treating it as an indication-specific procedure rather than an automatic companion to decompression.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
